Predicting recurrence risk in liver cancer patients after treatment
The First Affiliated Hospital, Zhejiang University School of Medicine
This study is trying to see if factors like sleep quality and mental health can help predict the chances of liver cancer coming back after treatment with radiofrequency ablation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Sex | All |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06577272 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a predictive model for assessing the risk of recurrence in patients with Hepatocellular Carcinoma (HCC) following radiofrequency ablation (RFA). It investigates the impact of various factors, including sleep quality and psychological conditions such as anxiety and depression, on post-RFA recurrence rates. Data will be collected from HCC patients who have undergone RFA for the first time, and advanced statistical methods will be employed to analyze the relationships between these factors and recurrence. The model will be validated using both internal and external datasets to ensure its reliability and applicability.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with primary HCC who are undergoing RFA as their initial treatment and can complete follow-up assessments.
Not a fit: Patients with vascular invasion, extrahepatic metastasis, or severe organ dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this model could help identify high-risk patients and enable timely interventions to prevent cancer recurrence.
How similar studies have performed: Other studies have explored predictive modeling in cancer recurrence, but this specific approach incorporating psychological factors is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ① Diagnosed as primary HCC according to the diagnostic criteria for primary liver cancer in China; ② Either a solitary tumor with a diameter less than 5 cm or 2-3 tumors each with a maximum diameter less than 3 cm; ③ RFA as the initial treatment; ④ Agreed to participate in the study and submitted the completed questionnaire survey; ⑤ A follow-up period exceeding 6 months after ablation. Exclusion Criteria: * ① Vascular invasion or extrahepatic metastasis before ablation; ② Presence of intractable ascites or hepatic encephalopathy; ③ Severe hepatic and renal dysfunction or other substantial organ disorders; ④ Active infections before or after ablation; ⑤ A history of other malignancies; ⑥ Failure to submit a completed questionnaire survey; ⑦ Lost to follow-up before reaching an outcome.
Where this trial is running
Hangzhou, Zhejiang
- The First Affiliated Hospital of Zhejiang University — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Jiang tianan, Dr
- Email: tiananjiang@zju.edu.cn
- Phone: +86 18857127666
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.